Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2027-08-01
Target enrollment:
Participant gender:
Summary
Single- arm Phase II study evaluating the combination of mogamulizumab (MOGA) added on top of
standard of care dose adjusted EPOCH (DA-EPOCH) in patients with newly diagnosed or
relapsed/refractory (for CTCL only) aggressive T cell lymphoma including patients with Adult
T-cell leukemia/lymphoma (ATLL).